A medical device manufacturer was experiencing a high number of defects and errors in production.
A full 5-10% of the raw material had to be scrapped at various stages in the production path leading to higher RSP (recommended selling price) having to filter down the value chain which endangered the market share position.
Tytex performed an analysis of the production site including own inbound goods. Several recommendations were made leading to:
Tools to allow fewer production stops
Firmer regulations on calibrating of the machinery
Benchmarked monitoring of performance through-out the site
Better suited raw materials
Marketing’s present target for RSP could be maintained
Performance and job satisfaction rates among staff went up by double digits
Tytex R&D involved in LEAN continuous improvement programme with partner